Drug Profile
MK 0873
Alternative Names: MK-0873Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Antibronchitics; Antipsoriatics; Antirheumatics
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Psoriasis
- Discontinued Chronic obstructive pulmonary disease; Rheumatoid arthritis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Psoriasis in USA (Topical, Cream)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Psoriasis in USA (Topical, Patch)
- 01 May 2014 Merck terminates phase II trial in Chronic obstructive pulmonary disease in Colombia (NCT00132730)